Pharmaceutical composition for treatment of lower urinary tract diseases

A composition and drug technology, applied in the field of medicine, can solve the problems of dry eyes, dry mouth, heart palpitations, lethargy, constipation, unbearable for patients, low efficacy and the like

Inactive Publication Date: 2007-09-26
SHENZHEN AUSA PHARM CO LTD
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Antimuscarinic drugs are the basic drugs for the treatment of overactive bladder, but the efficacy of these drugs is low, and the adverse reactions such as dry eyes, dry mouth, heart palpitations, drowsiness, and constipation are unbearable for some patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Embodiment 1 prepares the compound terazosin amlodipine tablet containing 1mg terazosin and 5mg amlodipine

[0060] Recipe: Terazosin 1g

[0061] Amlodipine 5g

[0062] Lactose 50g

[0063] Microcrystalline Cellulose 50g

[0064] Starch 10g

[0065] Sodium carboxymethyl starch 30g

[0066] Magnesium Stearate 1g

[0067] Preparation method: Contain 5g amlodipine (using amlodipine besylate, purchased from Pfizer Pharmaceutical Co., Ltd. (Dalian, China), its consumption is converted into 5g according to the molecular weight of amlodipine besylate and the molecular weight of amlodipine The amount of amlodipine besylate of amlodipine), 1g terazosin (use terazosin hydrochloride, purchased from Beijing Secco Pharmaceutical Co., Ltd., its consumption is according to the molecular weight and characteristic of terazosin hydrochloride The molecular weight of terazosin is converted into the amount of terazosin hydrochloride containing 1g te...

Embodiment 2

[0068] Embodiment 2 prepares the compound terazosin amlodipine tablet containing 2mg terazosin and 5mg amlodipine

[0069]Recipe: Terazosin 2g

[0070] Amlodipine 5g

[0071] Lactose 50g

[0072] Microcrystalline Cellulose 50g

[0073] Starch 10g

[0074] Sodium carboxymethyl starch 30g

[0075] Magnesium Stearate 1g

[0076] The preparation method is the same as in Example 1. In the 1000 compound tablets made, each tablet contains terazosin 2mg and amlodipine 5mg, and its mass ratio is 2:5.

Embodiment 3

[0077] Embodiment 3 prepares the compound terazosin amlodipine tablet containing 2mg terazosin and 2.5mg amlodipine

[0078] formula:

[0079] Terazosin 2g

[0080] Amlodipine 2.5g

[0081] Dextrin 30g

[0082] Microcrystalline Cellulose 40g

[0083] Low-substituted hydroxypropyl cellulose 30g

[0084] Sodium carboxymethyl starch 20g

[0085] Magnesium Stearate 1g

[0086] The preparation method is the same as in Example 1. In the 1000 compound tablets made, each tablet contains terazosin 2mg and amlodipine 2.5mg, and its mass ratio is 4:5.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a drug compound for treating disease of lower urinary tract, which comprises drug active component, drug carrier or shaping agent, wherein the drug active component is terraazoles and amiloripin. The disease of lower urinary tract relates to prostatitis increment, lower urinary tract syndrome and bladder excessive activities, in particular to treat lower urinary tract syndrome and bladder excessive activities induced by prostatitis increment. And the inventive drug can be used treat the high blood pressure concomitant with lower urinary tract, to effectively control blood pressure and resolve the lower urinary tract disease, compared with single terraazoles or amiloripin drug, to improve the health quality of patient.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating lower urinary tract diseases, in particular to a pharmaceutical composition for treating benign prostatic hyperplasia, lower urinary tract syndrome and overactive bladder. The invention belongs to the field of medicine. Background technique [0002] Benign prostatic hyperplasia (benign prostate hyperplasia, BPH) is the most common chronic disease among middle-aged and elderly men, and its incidence increases with the aging of the social population. Epidemiological survey of adult benign prostatic hyperplasia in Shanghai shows that the prevalence of benign prostatic hyperplasia in men aged 60 is 50% [Shi Rong, Wang Yixin, Jing Jing. Epidemiological survey of benign prostatic hyperplasia in Shanghai adults. Journal of Shanghai Second Medical University, 1999, 19(3): 27-22.]. A survey of 3,361 elderly people over 60 years old in six cities found that the total incidence of BPH was 43.68%...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/517A61P13/08A61P13/10A61P9/12A61K31/4422
Inventor 徐希平邢厚恂陈光亮刘海鹏秦献辉陈明侠于多徐艳龙李华王燕
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap